Approval - Peptide Review Desk

An expert panel maps out how to use the first two MASH drugs

September 14, 2026 by Marissa Cole

Peptide Review Desk news card: a framework for the first MASH drugs

For most of the time this site has covered semaglutide, the scarring form of fatty liver disease had no approved drug treatment at all. That has changed. An international expert panel writing in Gut on 11 September 2026 has published a clinical practice update for the two therapies now conditionally approved by the FDA for … Read more

FDA approves Mounjaro to lower cardiovascular risk in type 2 diabetes

August 30, 2026August 28, 2026 by Marissa Cole

The FDA has approved a new indication for Mounjaro (tirzepatide): lowering the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with type 2 diabetes who are at high risk for them. Eli Lilly announced the approval on 28 August 2026. It is the first cardiovascular … Read more